Nanoviricides (NNVC) Other Non-Current Liabilities (2013 - 2019)
Nanoviricides (NNVC) posted Other Non-Current Liabilities of $1.6 million for Q1 2019, up 10212.1% sequentially from $15449.0 in Q2 2018, and up 76.54% YoY from $902426.0 in Q1 2018.
Nanoviricides (NNVC) Other Non-Current Liabilities (2013 - 2019) Analysis & Trends
Nanoviricides has reported Other Non-Current Liabilities for 6 years, with the latest figure at $1.6 million in Q1 2019.
- Quarterly Other Non-Current Liabilities rose 76.54% year-over-year to $1.6 million in Q1 2019, while the trailing twelve-month figure through Mar 2019 was $1.6 million (up 76.54% YoY) and the FY2018 annual result came in at $15449.0, changed N/A from the prior year.
- Other Non-Current Liabilities climbed to $1.6 million in Q1 2019 per NNVC's latest filing, from $15449.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $1.6 million in Q1 2019 and troughed at $15449.0 in Q2 2018.
- A 4-year average of $563570.4 and a median of $476289.0 in 2015 frame the typical range for Other Non-Current Liabilities.
- The widest YoY moves for Other Non-Current Liabilities: up 76.54% in 2019, down 76.54% in 2019.
- Over 4 years, Other Non-Current Liabilities stood at $476289.0 in 2015, then tumbled by 94.06% to $28284.0 in 2016, then slumped by 45.38% to $15449.0 in 2018, then soared by 10212.1% to $1.6 million in 2019.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $1.6 million, $15449.0, and $902426.0 for Q1 2019, Q2 2018, and Q1 2018 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - |
| 10 | Nanoviricides | 29.06 Mn | 25.85 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | 1.59 Mn |
| Jun 30, 2018 | 15,449.00 |
| Mar 31, 2018 | 902,426.00 |
| Dec 31, 2016 | 28,284.00 |
| Sep 30, 2016 | 120,123.00 |
| Jun 30, 2015 | 476,289.00 |
| Mar 31, 2015 | 809,305.00 |
| Dec 31, 2014 | 9.41 Mn |
| Sep 30, 2014 | 3.79 Mn |
| Sep 30, 2013 | 7.89 Mn |
| Jun 30, 2013 | 3.75 Mn |